PRC
CORT icon

Pearl River Capital’s Corcept Therapeutics CORT Stock Holding History

Pearl River Capital’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-24,954
Closed -$811K – 511
2023
Q4 		$811K Buy
24,954
+2,195
+10% +$60.3K 0.13% 233
2023
Q3 		$620K Buy
+22,759
New +$659K 0.1% 296
2023
Q1 		– Sell
-12,950
Closed -$263K – 515
2022
Q4 		$263K Sell
12,950
-2,308
-15% -$57.9K 0.04% 430
2022
Q3 		$391K Sell
15,258
-551
-3% -$14.7K 0.07% 326
2022
Q2 		$376K Buy
15,809
+3,482
+28% +$75.9K 0.09% 309
2022
Q1 		$278K Buy
+12,327
New +$262K 0.08% 322

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Pearl River Capital's CORT Position: Q1 2024 in Review

Pearl River Capital sold out of Corcept Therapeutics (CORT) in Q1 2024, closing a stake of 24,954 shares — an estimated $811K sold.

Pearl River Capital first reported a position in CORT in Q1 2022 and held it in 6 quarters. The position peaked at $811K in Q4 2023. 287 funds tracked by Wall St. Rank hold CORT as of Q1 2024.

  • Pearl River Capital reported no remaining Corcept Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Pearl River Capital sold 24,954 Corcept Therapeutics shares in Q1 2024, an estimated $811K.
  • Pearl River Capital first reported a position in Corcept Therapeutics in Q1 2022 and held it in 6 quarters.
  • Pearl River Capital's Corcept Therapeutics position peaked at $811K in Q4 2023.
  • 287 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2024.

Based on Pearl River Capital's 13F filing for Q1 2024, filed 14 May 2024.